

Juan J Gomez-Reino

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/109904/juan-j-gomez-reino-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237
papers

22,531
citations

73
h-index

147
g-index

243
ext. papers

25,616
ext. citations

4.5
avg, IF

6.37
L-index

#	Paper	IF	Citations
237	Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. <i>Clinical Rheumatology</i> , 2021 , 40, 3979-3988	3.9	1
236	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021 , 60, 256-262	3.9	8
235	Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs. <i>Reumatología Clínica</i> , 2021 , 17, 160-169	0.9	2
234	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	6
233	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , 2020 , 93, 100601	2.4	3
232	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 988-990	2.4	48
231	Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. <i>Arthritis Research and Therapy</i> , 2020 , 22, 143	5.7	4
230	Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2020 , 179-203	0.3	
229	Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020 , 2, 459-470	2.5	3
228	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1226-1237	5.3	3
227	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020 , 2, 543-554	3.5	2
226	The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs. <i>Pharmacological Research</i> , 2019 , 148, 104410	10.2	4
225	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1536-1544	2.4	23
224	Visfatin as a therapeutic target for rheumatoid arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 607-618	6.4	12
223	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019 , 14, e0213073	3.7	16
222	Abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 319-326	5.1	9
221	Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. <i>Rheumatology International</i> , 2019 , 39, 509-515	3.6	19

220	Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 331-339	9.5	10
219	Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 690-698	2.4	46
218	Spanish transcultural adaptation and validation of the English version of the compliance questionnaire in rheumatology. <i>Rheumatology International</i> , 2018 , 38, 467-472	3.6	6
217	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018 , 4, e000615	5.9	18
216	Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2018 , 195, 181-190	4.9	100
215	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. <i>RMD Open</i> , 2018 , 4, e000669	5.9	19
214	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2018 , 8, 7342	4.9	11
213	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. <i>PLoS ONE</i> , 2018 , 13, e0196793	3.7	9
212	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2018 , 391, 2213-2224	4.0	113
211	Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2017 , 36, 1167-1172	3.9	3
210	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017 , 44, 162-169	4.1	13
209	Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 149-156	5.3	52
208	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	7.4	1649
207	Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naïve or Free of Methotrexate for 6 Months: the AMBITION Study. <i>Journal of Rheumatology</i> , 2017 , 44, 142-146	4.1	20
206	Leptin in the interplay of inflammation, metabolism and immune system disorders. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 100-109	8.1	259
205	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2017 , 56, 689-697	3.9	18
204	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1598-1602	2.4	45
203	Adipokines induce pro-inflammatory factors in activated Cd4+ T cells from osteoarthritis patient. <i>Journal of Orthopaedic Research</i> , 2017 , 35, 1299-1303	3.8	20

202	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5	125
201	Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. <i>PLoS ONE</i> , 2017 , 12, e0180144	3.7	15
200	The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 687-95	2.4	119
199	Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. <i>Rheumatology</i> , 2016 , 55, 523-34	3.9	66
198	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. <i>Rheumatology International</i> , 2016 , 36, 1043-63	3.6	24
197	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016 , 18, 50	5.7	27
196	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
195	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
194	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. <i>PLoS ONE</i> , 2016 , 11, e0153140	3.7	16
193	Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies. <i>PLoS ONE</i> , 2016 , 11, e0161141	3.7	28
192	Specific premature epigenetic aging of cartilage in osteoarthritis. <i>Aging</i> , 2016 , 8, 2222-2231	5.6	28
191	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1133-8	2.4	134
190	Therapy: The NICE position on indications for biologics and biosimilars. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 255-6	8.1	1
189	Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 564-8	2.4	33
188	Predictors of treatment failure and mortality in native septic arthritis. <i>Clinical Rheumatology</i> , 2015 , 34, 1961-7	3.9	23
187	Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice. <i>Journal of Bone and Mineral Metabolism</i> , 2015 , 33, 383-91	2.9	4
186	Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain. <i>Reumatología Clínica (English Edition)</i> , 2015 , 11, 144-150	0.1	
185	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. <i>Reumatología Clínica</i> , 2015 , 11, 144-50	0.9	2

184	FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015 , 16, 333-45	2.6	17
183	Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 117-27	9.5	95
182	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 362	5.7	139
181	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015 , 17, 157	5.7	26
180	Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 63	5.7	9
179	Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. <i>Arthritis Research and Therapy</i> , 2015 , 17, 233	5.7	86
178	SERPINE2 Inhibits IL-1 β -induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF- κ B/AP-1 Pathways. <i>PLoS ONE</i> , 2015 , 10, e0135979	3.7	31
177	Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 479-88	4.1	101
176	Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. <i>RMD Open</i> , 2015 , 1, e000017	5.9	59
175	The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. <i>Biomarkers</i> , 2015 , 20, 565-71	2.6	129
174	High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis: A Cross Sectional and Case Control Analysis Within the SUN Cohort. <i>Medicine (United States)</i> , 2015 , 94, e0924	1.8	43
173	Apremilast for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1281-90	3.0	6
172	New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history. <i>Drug Discovery Today</i> , 2015 , 20, 406-10	8.8	19
171	Predictors of response to TNF antagonists. <i>Current Pharmaceutical Design</i> , 2015 , 21, 221-32	3.3	4
170	Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. <i>Rheumatology</i> , 2014 , 53, 834-8	3.9	26
169	Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 871-82	2.4	45
168	Differential expression of adipokines in infrapatellar fat pad (IPFP) and synovium of osteoarthritis patients and healthy individuals. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 631-3	2.4	48
167	Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2014 , 9, 945-57	6.2	9

166	Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2014 , 16, R128	5.7	8
165	Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 298-305	2.4	39
164	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1020-6	2.4	305
163	An update on leptin as immunomodulator. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 1165-70	5.1	34
162	Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2924-37	9.5	112
161	Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study. <i>Arthritis Research and Therapy</i> , 2014 , 16, 436	5.7	5
160	Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. <i>Rheumatology</i> , 2014 , 53, 1872-85	3.9	101
159	Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies. <i>Arthritis and Rheumatology</i> , 2014 , 66, 940-9	9.5	88
158	NUCB2/nesfatin-1: a new adipokine expressed in human and murine chondrocytes with pro-inflammatory properties, an in vitro study. <i>Journal of Orthopaedic Research</i> , 2014 , 32, 653-60	3.8	24
157	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014 , 16, R66	5.7	17
156	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 238-45	1.9	25
155	Adipokines, metabolic syndrome and rheumatic diseases. <i>Journal of Immunology Research</i> , 2014 , 2014, 343746	4.5	96
154	Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014 , 16, 414	5.7	21
153	Potential role of apremilast for the treatment of psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 259-266	1.5	
152	Health-related quality of life in psoriatic arthritis patients in Spain. <i>Reumatología Clínica</i> , 2014 , 10, 25-31	0.9	14
151	Facteur rhumatoïde et réponse aux anti-TNF dans la polyarthrite rhumatoïde : revue systématique et méta-analyse d'études observationnelles. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014 , 81, 58-68	0.1	
150	Practice guidelines for the use of subcutaneous abatacept. <i>Reumatología Clínica</i> , 2014 , 10, 218-26	0.9	2
149	Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies. <i>Joint Bone Spine</i> , 2014 , 81, 41-50	2.9	18

148	Adipokines as drug targets in joint and bone disease. <i>Drug Discovery Today</i> , 2014 , 19, 241-58	8.8	46
147	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. <i>Rheumatology International</i> , 2014 , 34, 1059-63	3.6	17
146	Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. <i>JAMA Internal Medicine</i> , 2013 , 173, 1416-28	11.5	107
145	Abatacept use in rheumatoid arthritis: evidence review and recommendations. <i>Reumatologia Clínica</i> , 2013 , 9, 5-17	0.9	15
144	Reply: Pathogenic relevance of anti-citrullinated vimentin antibodies: comment on the article by Montes et al. <i>Arthritis and Rheumatism</i> , 2013 , 65, 542		
143	Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF dans la polyarthrite rhumatoïde : expérience de trois centres. <i>Revue Du Rhumatisme (Edition Française)</i> , 2013 , 80, 527-528	0.1	1
142	Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience. <i>Joint Bone Spine</i> , 2013 , 80, 438-40	2.9	3
141	Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. <i>Journal of Rheumatology</i> , 2013 , 40, 768-80	4.1	96
140	Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 9-17	5.3	58
139	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 583-9	2.4	68
138	The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 315-326	1.5	3
137	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 83-8	2.4	44
136	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
135	Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1830-5	2.4	109
134	Nitric oxide boosts TLR-4 mediated lipocalin 2 expression in chondrocytes. <i>Journal of Orthopaedic Research</i> , 2013 , 31, 1046-52	3.8	25
133	Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. <i>Arthritis Care and Research</i> , 2013 , 65, 2024-31	4.7	38
132	Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies. <i>Arthritis Research and Therapy</i> , 2013 , 15, R82	5.7	1
131	Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study. <i>PLoS ONE</i> , 2013 , 8, e58616	3.7	12

130 Adipokines, Molecular Players at the Crossroad Between Inflammation and Oxidative Stress: Role in Arthropathies **2013**, 67-88

129 Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. *Annals of the Rheumatic Diseases*, **2012**, 71, 1861-4 2.4 64

128 Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. *Journal of Proteomics*, **2012**, 77, 372-82 3.9 38

127 Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. *Annals of the Rheumatic Diseases*, **2012**, 71, 382-5 2.4 58

126 Association of anti-citrullinated vimentin and anti-citrullinated Enolase antibodies with subsets of rheumatoid arthritis. *Arthritis and Rheumatism*, **2012**, 64, 3102-10 19

125 Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. *Seminars in Arthritis and Rheumatism*, **2012**, 42, 89-103 5.3 46

124 Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1 α and IL-6 in J774 macrophages and in ATDC5 chondrocytes. *Life Sciences*, **2012**, 91, 1229-35 6.8 63

123 Association of a BMP5 microsatellite with knee osteoarthritis: case-control study. *Arthritis Research and Therapy*, **2012**, 14, R257 5.7 5

122 Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. *Arthritis Research and Therapy*, **2012**, 14, R94 5.7 6

121 Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a European cases only study. *PLoS ONE*, **2012**, 7, e45356 3.7 25

120 Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations. *Journal of Rheumatology*, **2012**, 39, 1509-16 4.1 21

119 Genetic risk load and age at symptom onset of knee osteoarthritis. *Journal of Orthopaedic Research*, **2012**, 30, 905-9 3.8 5

118 A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. *Arthritis and Rheumatism*, **2012**, 64, 970-81 258

117 Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. *Arthritis and Rheumatism*, **2012**, 64, 2504-17 151

116 Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to tumor necrosis factor-induced apoptosis. *Arthritis and Rheumatism*, **2012**, 64, 2460-70 26

115 Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. *Rheumatology*, **2012**, 51 Suppl 5, v31-7 3.9 23

114 Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. *Annals of the Rheumatic Diseases*, **2012**, 71, 374-7 2.4 52

113 Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. *Mediators of Inflammation*, **2012**, 2012, 125458 4.3 49

112	Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naïve subjects with rheumatoid arthritis: the phase III FILM trial. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1289-96	2.4	38
111	Adiponectin and leptin induce VCAM-1 expression in human and murine chondrocytes. <i>PLoS ONE</i> , 2012 , 7, e52533	3.7	73
110	Infections in patients with rheumatic diseases treated with TNF antagonists. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 1418-25	2.6	5
109	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A13.2-A14	2.4	
108	Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations. <i>Reumatología Clínica (English Edition)</i> , 2011 , 7, 30-44	0.1	
107	What's new in our understanding of the role of adipokines in rheumatic diseases?. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 528-36	8.1	207
106	Adiponectin and leptin increase IL-8 production in human chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2052-4	2.4	57
105	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
104	Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. <i>Arthritis Research and Therapy</i> , 2011 , 13, R80	5.7	10
103	Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 864-7	2.4	85
102	Beyond fat mass: exploring the role of adipokines in rheumatic diseases. <i>Scientific World Journal, The</i> , 2011 , 11, 1932-47	2.2	49
101	Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 40, 330-7	5.3	38
100	Cancer in patients with rheumatic diseases exposed to TNF antagonists. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 71-80	5.3	76
99	Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 524-33	5.3	34
98	Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. <i>BioFactors</i> , 2011 , 37, 413-20	6.1	127
97	Sustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1949-56	2.4	57
96	Efficacy and safety of the human anti-IL-1 β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. <i>BMC Musculoskeletal Disorders</i> , 2011 , 12, 153 ^{2.8}		95
95	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520

94	Particular association of clinical and genetic features with autoimmunity to citrullinated ßenolase in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 654-61		30
93	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1575-80	2.4	157
92	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. <i>Rheumatology</i> , 2011 , 50, 1999-2004	3.9	36
91	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology</i> , 2011 , 50, 85-92	3.9	29
90	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
89	The risk of tuberculosis in patients treated with TNF antagonists. <i>Expert Review of Clinical Immunology</i> , 2011 , 7, 329-40	5.1	32
88	Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 551-9	2.4	94
87	Association of systemic lupus erythematosus clinical features with European population genetic substructure. <i>PLoS ONE</i> , 2011 , 6, e29033	3.7	13
86	Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. <i>Journal of International Medical Research</i> , 2010 , 38, 1213-24	1.4	97
85	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1751-5	2.4	84
84	CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2013-6	2.4	47
83	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
82	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010 , 36, 1185-206	13.6	360
81	Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1010-4	2.4	113
80	At the crossroad between immunity and metabolism: focus on leptin. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 801-8	5.1	61
79	Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. <i>Arthritis Research and Therapy</i> , 2010 , 12, R224	5.7	34
78	Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R72	5.7	35
77	Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. <i>Arthritis Research and Therapy</i> , 2010 , 12, R33	5.7	43

76	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 631-7	2.4	1300
75	Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 88-96	2.4	589
74	Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. <i>Science Translational Medicine</i> , 2010 , 2, 52ra72	17.5	677
73	Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1675-82		72
72	New sequence variants in HLA class II/III region associated with susceptibility to knee osteoarthritis identified by genome-wide association study. <i>PLoS ONE</i> , 2010 , 5, e9723	3.7	79
71	Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 583-91	6.4	11
70	Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. <i>Human Molecular Genetics</i> , 2009 , 18, 1518-23	5.6	42
69	Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1870-7	2.4	232
68	Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. <i>Journal of Molecular Endocrinology</i> , 2009 , 43, 11-8	4.5	68
67	Adipokines as novel modulators of lipid metabolism. <i>Trends in Biochemical Sciences</i> , 2009 , 34, 500-10	10.3	142
66	DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. <i>BMC Musculoskeletal Disorders</i> , 2009 , 10, 91	2.8	21
65	Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009 , 60, 976-86		467
64	Expression and modulation of ghrelin O-acyltransferase in cultured chondrocytes. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1704-9		36
63	Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1710-21		150
62	Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2558-64		53
61	Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, eotaxin-3, and MHC2TA. <i>Journal of Rheumatology</i> , 2009 , 36, 1590-5	4.1	12
60	Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. <i>Arthritis Research and Therapy</i> , 2009 , 11, R69	5.7	112
59	Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. <i>Arthritis Research and Therapy</i> , 2009 , 11, R42	5.7	43

58	Poly(ADP-ribose) polymerase suppression protects rheumatoid synovial fibroblasts from Fas-induced apoptosis. <i>Rheumatology</i> , 2009 , 48, 483-9	3.9	8
57	Leptin beyond body weight regulation—current concepts concerning its role in immune function and inflammation. <i>Cellular Immunology</i> , 2008 , 252, 139-45	4.4	144
56	A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2008 , 16, 1101-9	6.2	208
55	Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage. <i>BMC Molecular Biology</i> , 2008 , 9, 17	4.5	64
54	Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 435-41		33
53	Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1264-74		76
52	A broad analysis of IL1 polymorphism and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1947-57		27
51	Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2968-80		670
50	Adipokines as emerging mediators of immune response and inflammation. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 716-24		386
49	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. <i>Arthritis and Rheumatism</i> , 2007 , 57, 756-61		313
48	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. <i>Rheumatology International</i> , 2007 , 27, 793-806	3.6	73
47	Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 560-1	2.4	10
46	Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1399-400	2.4	8
45	An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. <i>Human Molecular Genetics</i> , 2007 , 16, 2226-32	5.6	157
44	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 880-5	2.4	154
43	The emerging role of adipokines as mediators of inflammation and immune responses. <i>Cytokine and Growth Factor Reviews</i> , 2007 , 18, 313-25	17.9	274
42	Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. <i>Arthritis Research and Therapy</i> , 2006 , 8, R72	5.7	129
41	Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. <i>Arthritis Research and Therapy</i> , 2006 , 8, R55	5.7	49

40	Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. <i>Arthritis Research and Therapy</i> , 2006 , 8, R29	5.7	200
39	Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. <i>Arthritis Research and Therapy</i> , 2006 , 8, R1	5.7	33
38	Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. <i>Arthritis Research and Therapy</i> , 2006 , 8, R14	5.7	26
37	Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 1198-201	2.4	366
36	Leptin: a metabolic hormone that functions like a proinflammatory adipokine. <i>Drug News and Perspectives</i> , 2006 , 19, 21-6		71
35	Ghrelin in the Local Regulation of Endocrine Glands 2006 , 869-875		
34	Leptin, from fat to inflammation: old questions and new insights. <i>FEBS Letters</i> , 2005 , 579, 295-301	3.8	274
33	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1766-72		501
32	Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3015-9		24
31	Ghrelin plasmatic levels in patients with fibromyalgia. <i>Rheumatology International</i> , 2005 , 25, 6-8	3.6	7
30	Ghrelin, the same peptide for different functions: player or bystander?. <i>Vitamins and Hormones</i> , 2005 , 71, 405-32	2.5	17
29	A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004 , 50, 328-9		37
28	Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2590-7		99
27	Novel DNASE I mutations related to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004 , 50, 4070-1		27
26	Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor. <i>Respiratory Medicine</i> , 2004 , 98, 123-5	4.6	12
25	Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-gamma in human chondrocytes and ATDC5 chondrogenic cells. <i>Arthritis and Rheumatism</i> , 2003 , 48, 404-9		119
24	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2122-7		707
23	Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. <i>FEBS Letters</i> , 2003 , 552, 105-9	3.8	109

22	Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. <i>Arthritis and Rheumatism</i> , 1999 , 42, 989-92		122
21	Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. <i>Journal of Pathology</i> , 1999 , 188, 63-8	9.4	51
20	Internuclear ophthalmoplegia in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 179-86	5.3	21
19	Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. <i>Lupus</i> , 1998 , 7, 159-63	2.6	51
18	Apoptosis and proliferation of fibroblasts during postnatal skin development and scleroderma in the tight-skin mouse. <i>Journal of Histochemistry and Cytochemistry</i> , 1997 , 45, 711-9	3.4	31
17	Rheumatology. Inflammation and HIV infection: a friendly connection. <i>Lancet, The</i> , 1996 , 348 Suppl 2, s1124	4.0	0
16	Outcome of silent lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 1996 , 26, 468-76	5.3	43
15	Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1869-74		7
14	Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. <i>Arthritis and Rheumatism</i> , 1996 , 39, 2028-34		79
13	Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities. <i>Clinical Immunology and Immunopathology</i> , 1995 , 76, 115-9		4
12	Invasive aspergillosis in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1995 , 24, 304-14	5.3	42
11	Clonally expanded lymphocytes in the minor salivary glands of Sjögren's syndrome patients without lymphoproliferative disease. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1441-4		37
10	Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1528-33		76
9	Nontropical pyomyositis in adults. <i>Seminars in Arthritis and Rheumatism</i> , 1994 , 23, 396-405	5.3	77
8	Differential contribution of C4 and HLA-DQ genes to systemic lupus erythematosus susceptibility. <i>Human Genetics</i> , 1993 , 91, 579-84	6.3	16
7	Factor B activation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1990 , 33, 1598-9		2
6	Both HLA class II and class III DNA polymorphisms are linked to juvenile rheumatoid arthritis susceptibility. <i>Clinical Immunology and Immunopathology</i> , 1990 , 56, 22-8		21
5	Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 18, 189-97	5.3	59

4	An Eco RI polymorphic site in the human complement C4 gene distinguishes juvenile rheumatoid arthritis (JRA) susceptibility-bearing haplotypes. <i>Molecular Immunology</i> , 1989 , 26, 427-30	4.3	8
3	A review of peripheral tuberculous arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1988 , 18, 142-9	5.3	98
2	Bf polymorphisms in systemic lupus erythematosus patients of Spanish descent. <i>Arthritis and Rheumatism</i> , 1986 , 29, 932-3		5
1	Pseudoaneurysm of the popliteal artery as a complication of an osteochondroma. <i>Skeletal Radiology</i> , 1979 , 4, 26-8	2.7	10